CAM
ALXN

Capstone Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Capstone Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$2.47M Sell
20,292
-840
-4% -$97.8K 0.07% 338
2017
Q1 		$2.56M Sell
21,132
-620
-3% -$79.9K 0.07% 329
2016
Q4 		$2.66M Sell
21,752
-2,948
-12% -$361K 0.08% 307
2016
Q3 		$3.03M Buy
24,700
+127
+0.5% +$16.3K 0.09% 279
2016
Q2 		$2.87M Buy
24,573
+1,095
+5% +$155K 0.09% 277
2016
Q1 		$3.27M Buy
23,478
+1,218
+5% +$179K 0.09% 268
2015
Q4 		$4.25M Buy
22,260
+954
+4% +$167K 0.12% 207
2015
Q3 		$3.33M Buy
21,306
+1,347
+7% +$246K 0.1% 251
2015
Q2 		$3.61M Buy
19,959
+413
+2% +$71.3K 0.1% 249
2015
Q1 		$3.39M Buy
19,546
+447
+2% +$80.9K 0.1% 259
2014
Q4 		$3.53M Buy
19,099
+4,725
+33% +$876K 0.1% 251
2014
Q3 		$2.38M Buy
14,374
+305
+2% +$50.1K 0.08% 289
2014
Q2 		$2.2M Sell
14,069
-2,672
-16% -$422K 0.07% 317
2014
Q1 		$2.55M Sell
16,741
-2,318
-12% -$369K 0.08% 301
2013
Q4 		$2.53M Sell
19,059
-12,276
-39% -$1.47M 0.07% 309
2013
Q3 		$3.64M Buy
31,335
+270
+0.9% +$29.6K 0.09% 255
2013
Q2 		$2.87M Buy
+31,065
New +$2.99M 0.08% 299

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capstone Asset Management's ALXN Position: Q2 2017 in Review

Capstone Asset Management reduced its Alexion Pharmaceuticals (ALXN) stake by 4% in Q2 2017, selling an estimated $97.8K and leaving 20,292 shares worth $2.47M. The position accounts for 0.07% of the portfolio, ranked #338.

Capstone Asset Management first reported a position in ALXN in Q2 2013 and has held it in 17 quarters since. The position peaked at $4.25M in Q4 2015. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Capstone Asset Management held 20,292 shares of Alexion Pharmaceuticals worth $2.47M as of Q2 2017.
  • Capstone Asset Management sold 840 Alexion Pharmaceuticals shares in Q2 2017, an estimated $97.8K.
  • Alexion Pharmaceuticals made up 0.07% of Capstone Asset Management's portfolio in Q2 2017, its #338 holding.
  • Capstone Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • Capstone Asset Management's Alexion Pharmaceuticals position peaked at $4.25M in Q4 2015.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.